亚太药业(002370.SZ)：预计2025年净利润同比增长192.06%-250.47%

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) expects a significant increase in net profit for 2025, projecting a range of 100 million to 120 million yuan, representing a growth of 192.06% to 250.47% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 100 million to 120 million yuan for 2025, which marks a substantial increase from the previous year [1] - The expected operating revenue for the same period is projected to be between 350 million to 370 million yuan [1] - The company also forecasts a non-recurring loss of 42 million to 60 million yuan [1] Key Drivers - The primary reason for the anticipated profit increase is the sale of the wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., with the transaction expected to contribute approximately 149 million yuan to the total profit for 2025 (non-recurring gains) [1]